Family of DNA sequences found in prokaryotic organisms
POPULARITY
Categories
431 episodes with CRISPR
83 episodes with CRISPR
47 episodes with CRISPR
38 episodes with CRISPR
25 episodes with CRISPR
18 episodes with CRISPR
23 episodes with CRISPR
21 episodes with CRISPR
26 episodes with CRISPR
34 episodes with CRISPR
35 episodes with CRISPR
40 episodes with CRISPR
18 episodes with CRISPR
23 episodes with CRISPR
12 episodes with CRISPR
8 episodes with CRISPR
9 episodes with CRISPR
12 episodes with CRISPR
7 episodes with CRISPR
13 episodes with CRISPR
14 episodes with CRISPR
7 episodes with CRISPR
16 episodes with CRISPR
13 episodes with CRISPR
34 episodes with CRISPR
18 episodes with CRISPR
9 episodes with CRISPR
12 episodes with CRISPR
11 episodes with CRISPR
18 episodes with CRISPR
15 episodes with CRISPR
5 episodes with CRISPR
15 episodes with CRISPR
10 episodes with CRISPR
24 episodes with CRISPR
10 episodes with CRISPR
27 episodes with CRISPR
8 episodes with CRISPR
6 episodes with CRISPR
9 episodes with CRISPR
4 episodes with CRISPR
13 episodes with CRISPR
4 episodes with CRISPR
7 episodes with CRISPR
11 episodes with CRISPR
6 episodes with CRISPR
10 episodes with CRISPR
7 episodes with CRISPR
4 episodes with CRISPR
9 episodes with CRISPR
3 episodes with CRISPR
10 episodes with CRISPR
16 episodes with CRISPR
5 episodes with CRISPR
5 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
9 episodes with CRISPR
5 episodes with CRISPR
10 episodes with CRISPR
4 episodes with CRISPR
4 episodes with CRISPR
5 episodes with CRISPR
5 episodes with CRISPR
8 episodes with CRISPR
5 episodes with CRISPR
11 episodes with CRISPR
6 episodes with CRISPR
5 episodes with CRISPR
8 episodes with CRISPR
6 episodes with CRISPR
7 episodes with CRISPR
9 episodes with CRISPR
6 episodes with CRISPR
7 episodes with CRISPR
12 episodes with CRISPR
8 episodes with CRISPR
12 episodes with CRISPR
6 episodes with CRISPR
4 episodes with CRISPR
4 episodes with CRISPR
7 episodes with CRISPR
8 episodes with CRISPR
6 episodes with CRISPR
6 episodes with CRISPR
10 episodes with CRISPR
6 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
6 episodes with CRISPR
8 episodes with CRISPR
3 episodes with CRISPR
6 episodes with CRISPR
4 episodes with CRISPR
4 episodes with CRISPR
4 episodes with CRISPR
5 episodes with CRISPR
6 episodes with CRISPR
2 episodes with CRISPR
10 episodes with CRISPR
6 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
4 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
14 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
4 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
14 episodes with CRISPR
9 episodes with CRISPR
2 episodes with CRISPR
6 episodes with CRISPR
4 episodes with CRISPR
8 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
5 episodes with CRISPR
10 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
7 episodes with CRISPR
3 episodes with CRISPR
4 episodes with CRISPR
5 episodes with CRISPR
2 episodes with CRISPR
4 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
8 episodes with CRISPR
2 episodes with CRISPR
2 episodes with CRISPR
5 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
6 episodes with CRISPR
2 episodes with CRISPR
4 episodes with CRISPR
7 episodes with CRISPR
4 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
4 episodes with CRISPR
4 episodes with CRISPR
7 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
10 episodes with CRISPR
4 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
4 episodes with CRISPR
2 episodes with CRISPR
4 episodes with CRISPR
6 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
5 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
3 episodes with CRISPR
3 episodes with CRISPR
9 episodes with CRISPR
3 episodes with CRISPR
2 episodes with CRISPR
We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap
We are hearing a lot about gene Therapy and CRISPR technology. Mark's guest shared some wonderful healing examples and where we are going with this amazing science. Hear this from Dr. Lindsay George from CHOP about the exciting new health world ahead of us all on The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
In today's episode, I break down DNA, where it is found, and what it represents from a scientific and biblical standpoint. I discuss CRISPR, the genome, gene drives, and methylation. Is this innocent innovation or planned biological control and rewriting? #DNA #blood #Biblical #creation #CRISPR #genedrives #consent #coersion #control #accountability #GOD
Most receptors come with a history. Remulate came with a name — and almost nothing else. Dr. Beatriz Redondo, group leader at the University of Leipzig, has spent the last nine years building the first systematic characterization of adhesion GPCRs in Drosophila, including three receptors so new they were named after condiments. What she's constructing isn't just a receptor profile — it's a method for doing discovery when the tools don't exist yet.Dr. Redondo uses CRISPR, genetic tagging, and in vivo behavioral assays to place and characterize adhesion GPCRs in a system where generations turn over in weeks. Her work on remulate — a neuronal adhesion GPCR with a human ortholog linked to vascular malformations and blood-brain barrier dysfunction — is among the first of its kind in any organism.Key takeaways:Why Drosophila remains a productive system for receptor discovery in the genomics eraHow CRISPR and epitope tagging replace antibody-based tools for understudied GPCRsWhat nocifensive behavior in larvae reveals about remulate's neuronal functionHow basic science in an insect model connects to vertebrate disease biologyWhat it looks like to characterize a receptor from scratch — with no prior literature to build onDr. GPCR University — live and on-demand courses for scientists working on real discovery problems: https://www.ecosystem.drgpcr.com/gpcr-universityThis episode is supported by Eurofins DiscoverX and GeneTex: https://www.ecosystem.drgpcr.com/eurofins-discoverx | https://www.ecosystem.drgpcr.com/genetex
Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Este episodio especial está diseñado para sorprender a los oyentes con hechos reales sobre el futuro de la salud humana, alejándose de los fenómenos inexplicables tradicionales del programa para centrarse en los asombrosos avances de la ciencia médica actual. El guion explora cómo la convergencia de los datos masivos, la inteligencia artificial y la biología molecular ha acelerado la innovación de manera sin precedentes. A lo largo del programa, se detallan hitos revolucionarios que ya son una realidad, como las terapias génicas hiperpersonalizadas con CRISPR, el uso de la tecnología de ARN mensajero para combatir tumores específicos y los xenotrasplantes con órganos de cerdos modificados genéticamente. Además, se aborda la detección precoz del cáncer mediante biopsias líquidas, los enfoques científicos para la longevidad y los esfuerzos de la medicina regenerativa para construir nuevos tejidos desde cero. Sin embargo, el episodio mantiene una postura crítica y honesta al discutir también las sombras de esta revolución, cuestionando el alto costo de los tratamientos, la desigualdad en la investigación global y los profundos dilemas éticos que surgen al intervenir en la naturaleza humana. #LaRuedaDelMisterio #FuturoDeLaMedicina #CienciaYSalud #Biotecnología #MedicinaPersonalizada #CRISPR #Bioética laruedadelmisterio2010@gmail.com ®© La Rueda del MisterioEscucha este episodio completo y accede a todo el contenido exclusivo de La Rueda del Misterio. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/4754
Ginny Yurich sits down with Dr. Sina McCullough for one of the most eye-opening conversations we've had on The 1000 Hours Outside Podcast. Sina shares how a devastating health collapse led her from a PhD in nutrition to questioning everything she thought she knew about the American food system. Together they unpack why ultra-processed food is so cheap, how the farm bill reshaped the modern grocery store, and what's really happening with gene-edited foods, pharmaceutical crops, CRISPR technology, and the hidden chemicals most families never even realize they're consuming. But this episode is not rooted in fear. It's about remembering that our daily choices still matter, that real food can help the body heal, and that ordinary people have more power than they've been led to believe. This conversation will make you look at your pantry, your plate, and your family's future differently. Sign up for the Two Days of Truth here Check out Dr. Sina McCullough's new book: Hands Off My FoodCheck out the Beyond Labels podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
Send us Fan MailSubscribe and unleash your inner science goblin. We see you. We respect it.What happens when your DNA makes a typo?In this episode of Wildly Curious, Katy Reiss and Laura Fawks Lapole dive into the strange, fascinating world of genetic mutations—the tiny changes in DNA that can shape evolution, alter proteins, create disease, or sometimes do absolutely nothing at all. From harmless genetic quirks to serious inherited disorders, this episode breaks down some of the most important mutation types in a way that actually makes sense.
Dr. Adam Brockman brings you the stories redefining modern medicine—from CRISPR's new “molecular paper shredder,” a biotech breakthrough that targets sick cells with surgical precision, to a “crystal ball” blood test that may predict your biological future with uncanny accuracy. Discover how nature and innovation are teaming up: from Spirulina's B12 revolution for plant-based eaters, to Lyme's surprising connection with Alzheimer's, and the radical plan to stop infection at its source by vaccinating mice instead of humans. It's science meets real-world transformation—tune in and learn how to stay years ahead of your biology.Health Headlines of the WeekHealth Alternative of the WeekHealth Outrage of the WeekHealth Mystery of the Week
Fungi are “nature's biological recycling machines,” says guest Vayu Hill-Maini, a former chef turned bioengineer. That is, they take waste and turn it into good things. Hill-Maini now melds his scientific and culinary skills to create new foods, but also medicines, faux leather, pigments and other valuable products from mushrooms and molds. He uses CRISPR gene editing technology to “domesticate” these fungi – removing off-flavors and increasing nutritional content to make new-age cheeses, burgers, salami, and more. “We call it the DBTL cycle – design, build, taste, learn,” Hill-Maini tells host Russ Altman about his creative process on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Vayu Hill-Maini Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Vayu Hill-Maini, a professor of bioengineering at Stanford University. (00:03:33) From Chef to Bioengineer How Hill-Maini's culinary background led him to study food through science. (00:05:23) Building a Lab with a Kitchen Why his Stanford lab combines bioengineering research with culinary experimentation. (00:07:32) What Are Fungi? A primer on yeasts, molds, mushrooms, and their role in food and medicine. (00:10:22) Domesticating Fungi How humans have shaped fungi over thousands of years. (00:14:23) Mushrooms as a Food Source The nutrients, proteins, vitamins, and beneficial molecules found in fungi. (00:16:21) Fungi as Biological Recyclers Using fungi to turn food waste, agricultural waste, and other materials into useful products. (00:18:22) Making Waste-Based Foods Desirable Why taste, emotion, and culinary design matter for sustainable foods. (00:20:22) Engineering Delicious Fungi Using genetics and CRISPR to improve flavor, nutrition, and usability. (00:22:50) Gentle Genetic Tweaks Making small changes to reduce off-flavors or enhance useful traits. (00:23:46) Design, Build, Taste, Learn How the lab moves between kitchen and bench science to improve foods. (00:24:06) Chefs in the Lab How culinary collaborators help guide research and creativity. (00:28:58) Fungi-Based Materials The potential to create textiles, leather alternatives, and building materials. (00:31:03) Future In a Minute Rapid-fire Q&A: sustainability, students, and the promise of fungi. (00:33:25) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode of the AgCulture Podcast, Paul sits down with Bob Miller, founder of Miller Hybrids, to unpack what it really takes to build a seed company in an industry dominated by global giants. From his early days in plant breeding to launching his own company in the middle of industry consolidation, Bob shares a perspective that challenges much of how modern seed is developed, tested, and sold.This conversation dives deep into why most seed is bred for “perfect conditions” instead of real farms, how Miller Hybrids tests genetics differently to create more stable performance, and why conventional corn is quietly making a comeback. Bob also breaks down the economics behind traits, the real role of GMOs, and where farmers may be overpaying for protection they don't actually need.If you've ever wondered whether bigger companies actually mean better seed—or what the future of genetics, CRISPR, and farm profitability really looks like—this episode will make you think differently about every seed decision you make.MEET THE GUESTBob Miller is a respected corn breeder and the founder and owner of Miller Hybrids, a family-owned seed company based in Kalona, Iowa.Born on a dairy and crop farm in northwest Ohio, Miller developed an early fascination with corn hybrids and their ability to handle stress and maximize yields. He built a distinguished career as a corn breeder with major seed companies, including Syngenta,where he developed successful commercial inbred lines and hybrids. His work emphasized improved emergence, yield stability, and drought tolerance.In 2005, he founded Miller Hybrids (originally B.O.B. Seeds, standing for "Best of the Best") to create a more hands-on, farmer-focused operation. As owner, president, and research director, Miller leads the company's breeding and testing programs. He develops corn hybrids tailored for the average farm, rigorously testing them across diverse soil types, stress conditions, and real-world environments like corn-on-corn rotations.Miller is deeply committed to empowering farmers. He believes in building reliable products that raise farm averages rather than chasing only top-end yields in ideal conditions. His family company (with his wife Pam) emphasizes personal attention, direct access to the breeder, and genetics that deliver stable, high performance for everyday growers.Through Miller Hybrids, Bob continues his lifelong passion for practical plant breeding, blending decades of industry expertise with the independence of a family business to support American agriculture.To learn more about Miller Hybrids, check out their website: https://www.millerhybrids.com/
Glen McGugan, Ph.D., Director of ASM's Mechanism Discovery Unit, discusses how curiosity‑driven research—from parasite virulence to CRISPR and complex microbial systems—drives tomorrow's breakthroughs. Ashley's Biggest Takeaways Mechanism discovery,encompasses all of the foundational basic research across the microbial sciences and is essential for all advances in microbial science. Many transformative technologies (e.g., CRISPR) originated from curiosity-driven, basic research rather than immediate practical goals. McGugan's experience as a Program Officer at NIH provided him with a broad perspective on the research pipeline, from basic science to clinical trials, and highlighted the importance of supporting early-career scientists. Developing therapeutics for parasitic diseases is particularly challenging due to complex life cycles and limited financial incentives for pharmaceutical companies; much of the progress relies on government and philanthropic funding. ASM's Mechanism Discovery Unit serves as a neutral hub to convene interdisciplinary stakeholders, foster collaboration, and advance fundamental research. Safeguarding future breakthroughs in the microbial sciences depends on the involvement of and connections between researchers, policymakers, funders and industry partners to close gaps between discovery, implementation and impact.
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Trevor Martin, Co-Founder and CEO of Mammoth Biosciences, a company at the forefront of next-generation CRISPR technologies. Co-founded alongside Nobel Prize-winning scientist Jennifer Doudna, Mammoth is building a platform to both detect and cure disease by harnessing the natural diversity of CRISPR systems.Trevor's journey into biology was anything but conventional—initially drawn to physics and chemistry, he discovered biology through an interdisciplinary lens that revealed its true complexity and potential for engineering. That shift ultimately led him to Stanford, where he began exploring the intersection of genetics, computation, and real-world impact.From there, this conversation traces the founding of Mammoth, the decision to pursue entrepreneurship over academia, and the ambition to build a generational biotech company—not just a single-asset success. Trevor shares how CRISPR is evolving from a breakthrough technology into a scalable platform capable of addressing a wide range of genetic diseases, with the potential to fundamentally reshape human health.At its core, this episode explores the convergence of science, entrepreneurship, and persistence—highlighting what it takes to translate cutting-edge research into real therapies, and why the next decade of biology may redefine what it means for genetics to determine our future.
Joined by Heidi Luv (Unfiltered Rise) to discuss blood doping, golden blood, Rh factor, and CRISPR technology. We delve into types of blood doping, military involvement, super soldiers, DARPA, and much more! Follow Heidi at https://open.spotify.com/show/4pzqktZNcGNZhzAeF9Zd3Q?si=BLmOZCUrTfe2o5XuGqYW7g www.unfilteredrisepodcast.com IG @unfilteredrise_podcast X @UnfilteredRise On Patreon #blooddoping #goldenblood #CRISPR #DNA #military #DARPA #supersoldiers #EPO #Autologous #syntheticoxygencarriers #bloodclots #damage #diseases #ATP #Rh #internationalregistry #blood #bloodcard #bloodlines #aliens #Nephilim
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative dynamics shaping the industry, from financial innovations to regulatory hurdles, each having profound implications for patients and stakeholders alike. The pharmaceutical and biotech industries are in the midst of a transformative period, grappling with the challenge of making advanced therapies, particularly cell and gene therapies, both financially sustainable and accessible. These treatments, often delivered in a single dose with curative potential, pose significant financial challenges due to their high upfront costs. The existing healthcare framework, especially in the U.S., struggles to accommodate these costs because of its reliance on annual insurance cycles and employer-based coverage. This issue is further exacerbated by the pricing strategies adopted by pharmaceutical companies, which often set high list prices to fulfill shareholder expectations while inadvertently creating barriers to accessibility. A notable proposal to address this challenge comes from Jennifer Hinkel, president of Sigla Sciences. She suggests a novel approach through the securitization of therapeutic risks—a financial innovation that holds potential to revolutionize funding for these therapies. Her model envisions a consortium of banks and hedge funds pooling resources to make immediate payments to pharmaceutical companies based on clinical success milestones. This setup allows risk distribution across payers through subscription fees, making high-cost therapies predictable rather than catastrophic expenses. Drawing parallels with parametric insurance models like weather derivatives, Hinkel's approach requires robust data infrastructure for tracking patient outcomes and standardized contracts for clarity in transactions. The successful implementation of this model necessitates bridging communication gaps between finance and biotech sectors, as both operate under different paradigms. Standardizing contracts akin to those used in mortgage-backed securities could further enhance clarity and comparability. Several key developments are essential for this model to materialize: building comprehensive data systems for accurate patient outcome tracking, creating uniform contracts to ease transaction complexities, fostering cross-sector communication for mutual understanding, adapting regulatory frameworks to support these financial instruments while safeguarding patient safety, and educating industry professionals on these innovations' benefits. The implications of such an approach could be groundbreaking, potentially reshaping how therapeutic risks are managed across stakeholders. Despite significant challenges like data infrastructure and cross-sector collaboration, the potential rewards justify further exploration. As biotech innovations continue with advancements like CRISPR gene editing and personalized medicine becoming more prevalent, sustainable financial models will be critical for ensuring these life-saving therapies reach those in need. Turning now to recent developments within the sector that highlight both scientific breakthroughs and regulatory challenges: AstraZeneca faced a setback with its oral selective estrogen receptor degrader camizestrant. An FDA panel voted against its use in first-line settings for hormone receptor-positive, HER2-negative metastatic breast cancer—a blow to AstraZeneca's strategy targeting $5 billion in peak sales. This decision underscores the regulatory hurdles involved in leveraging new mechanisms of action for cancer treatments, emphasizing the necessity for robust clinical data. In another significant shift, Johnson & Johnson has decided to discontinue its CAR-T cell therapy programs despite earlier projections of promising efficacy and potential peak sales Support the show
Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss.
Welcome to Pulse: Amplify, where we sit down with the leaders and changemakers shaping the future of health. In this episode Louise and George sit down with Dr Mehmood Khan, CEO of Hevolution Foundation, and Her Royal Highness Princess Dr Haya Bint Khaled Bin Bandar Al Saud, Senior Vice President of Research at Hevolution. Based in Riyadh and backed by Saudi Arabia's Vision 2030, Hevolution is the world's largest philanthropic funder of healthspan science, with over USD $400 million allocated in just three years.Timed with the release of the second edition of Hevolution's Global Healthspan Report - the most comprehensive look at the field across 23 countries - this conversation moves beyond the longevity hype to explore what it takes to extend healthy human life for the benefit of all.In this episode:Healthspan, not longevity - Why Hevolution is focused on keeping people physically, mentally, and financially independent, and why a global non-profit is the right vehicle for a challenge governments and private enterprise can't tackle alone.Why Saudi Arabia, why now - Princess Dr Haya on the demographic shift driving the kingdom's leadership, and why a young population on the brink of ageing is uniquely placed to redesign systems before they break.The science that has scientists excited - GLP-1 agonists, senotherapeutics, CRISPR, and cellular reprogramming, and why the real breakthrough is the convergence of these fields, not any one of them in isolation.A jaw-dropping case study - Dr Khan walks through how rejuvenating aged liver cells eliminated chronic Hepatitis B in animal models, with first-in-human trials now underway. A profound example of aging biology rewriting the rules for treating incurable diseases.What clinicians need to know - Two-thirds of healthcare professionals are now getting monthly healthspan questions from patients. Princess Dr Haya on the shift from reactive to proactive care, and the urgent need for evidence-based healthspan protocols.A message for policymakers - Why the Minister of Finance, not just the Minister of Health, needs to be at the table, and why retirement, education, and workforce policies built for a 1%-over-65 world are catastrophically out of date.Where digital health innovators should be looking - The five years that could be cut from drug development with better data tools, the four proven interventions that lend themselves to digital monitoring, and why we already have the technology - just not the policy frameworks to deploy it.Connect with Hevolution on LinkedInVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+IT
I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.Source Links for Further ResearchI. Rare Disease Advocacy and Funding (Conflicts of Interest)[TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)[TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)[TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)[TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)[NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)[NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/) [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)[Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)[NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)II. Gene Therapy (CRISPR), Risks, and Regulation [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)[CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)[CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)[FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)III. Vaccines, Toxins, and Environmental Amplification [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)[Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/) [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)[Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)IV. Alternative and Holistic Approaches[Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-(mtor)-pathway)[Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)[Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)[Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)contact Jill: pjlacy6@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care. Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the Indian pharmaceutical giant into international markets. This deal not only amplifies Sun Pharma's footprint but also integrates Organon's strong focus on women's health and biosimilars into its portfolio. It's a strategic move that underscores the increasing trend of cross-border mergers as companies seek to diversify and enhance their global presence. As the largest-ever overseas acquisition by an Indian firm, this transaction is emblematic of the growing importance of global consolidation in the pharma industry. Meanwhile, Astellas Pharma faces a mixed fiscal outlook with its prostate cancer drug Xtandi. While Xtandi experienced a modest sales increase in 2025, a projected decline for 2026 has prompted Astellas to pivot towards developing new medicines. This highlights the critical dependence on innovation within the industry to sustain growth, especially as competition intensifies. In the realm of ATTR amyloidosis treatments, Pfizer has reached a settlement with two generic manufacturers over its drug Vyndamax. This resolution is crucial in stabilizing the market amidst rising generic competition, which can significantly influence pricing and market dynamics. Such settlements are an integral part of maintaining competitive positioning in crowded therapeutic spaces. Ligand Pharmaceuticals' strategic purchase of XOMA for $739 million signals a broader trend of consolidation among biotech royalty aggregators. This acquisition aligns with Ligand's strategy to augment its portfolio through mergers and acquisitions—a recurring theme as biotech companies strive to streamline operations and expand their competitive edge. The competition within the oral GLP-1 market is intensifying, particularly with Eli Lilly's delayed launch of Foundayo inadvertently benefiting Novo Nordisk's market position. This rivalry underscores the fierce race to dominate the lucrative obesity management sector, highlighting how pivotal timing can be in gaining market share. The FDA's recent allocation of national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics marks a significant regulatory shift towards embracing psychedelic therapies. These vouchers could expedite development timelines, thereby accelerating patient access to novel treatments that have traditionally been underexplored. Thermo Fisher Scientific's robust start to 2026 showcases how strategic acquisitions like that of Clario can drive growth. This reflects broader industry trends where biopharma companies leverage technological advancements to enhance capabilities in clinical trial support and data management. In gene editing news, Intellia Therapeutics is advancing towards FDA approval for its in vivo CRISPR therapy following successful Phase 3 trials. This progress heralds a new era for gene editing technologies in treating genetic disorders, underscoring their potential to revolutionize therapeutic approaches. Eli Lilly continues its aggressive acquisition strategy by purchasing Ajax Therapeutics for $2.3 billion. This acquisition focuses on next-generation JAK inhibitors for myelofibrosis, aligning with Lilly's broader goal to diversify its pipeline and maintain its leadership in innovative therapeutics. Recent studies have also shed light on how an endoscopic procedure used in Europe can aid patients on Eli Lilly's tirzepatide in maintaining weight loss post-treatment. This finding could significantly impact long-term obesity management strategies, offering new insights into sustainaSupport the show
In this episode, Zeeshan talks with Will about how creative world building turned into a real drive to solve problems through biology and synthetic biology. Their conversation traces how BioBuilder helped Will gain mentors, lab confidence, and a clearer path from high school projects to Stanford bioengineering and early industry exposure.This episode includes a conversation about Will's• early curiosity rooted in ecosystems, energy flow, and creativity • why biology feels like a place he can build and contribute • what drew him to quorum sensing and bacterial communication • how reading about CRISPR sparked interest in synthetic biology • why BioBuilder matters for access and first-generation students • how he helped design projects that protect ecosystems • projects related to coral reef protection and tackling fertilizer runoff• mentorship moments that reshape what it means to be a scientist • presenting lightning talks, building communication skills, finding community • internships and research experiences that clarified industry versus academic paths • choice of Stanford for challenge and choosing bioengineering to translate research into impact • advice for 16-year-olds who feel intimidated, namely: show up, learn by doing, ask questions If you'd like to learn more or hear some of the other podcasts we've recorded, please go on to the BioBuilder website. Learn more about BioBuilder's programs for students, educators, and industry professionals here
The full quad is back and we're getting right into the tech drama: AI backlash (from Reese Witherspoon to everyday skepticism), breakthrough science like CRISPR entering its “it actually works” era, and major power shifts across tech — from Apple succession chatter to Jensen Huang's leadership moments and the brewing battle between OpenAI and Elon Musk. They squad digs into SpaceX IPO dynamics, the rise of “traces” data as the next AI battleground, and what happens when AI gives more people the power to build. Chapters:0:17 — Welcome Back: Full Quad Edition1:07 — Creatine, AI Stuffies, and the Opening Chaos4:37 — Breakthrough Prize & CRISPR Finally Working5:47 — One-of-One Gene Therapy Becomes Real7:07 — The AI Backlash Is Real8:47 — UBI vs. Meaning: The Real Debate10:57 — Jensen's “I Didn't Wake Up a Loser Today” Moment12:47 — Apple Succession: Tim Cook → John Ternus16:17 — Asset Prices vs. Reality21:17 — Elon vs. OpenAI: The Trial27:07 — SpaceX IPO: Biggest in History?29:27 — xAI, Cursor, and the $60B Bet36:07 — Traces Data: The Next AI Battleground40:07 — Workplace Surveillance & Employee Data48:27 — Who Gets to Build? (6B Users vs. 50M Builders)51:07 — AI: Equalizer or Concentrator?We're also on ↓X: https://twitter.com/moreorlesspodInstagram: https://instagram.com/moreorlessYouTube: https://youtu.be/bjePLXg64n0Connect with us here:1) Sam Lessin: https://x.com/lessin2) Dave Morin: https://x.com/davemorin3) Jessica Lessin: https://x.com/Jessicalessin4) Brit Morin: https://x.com/brit
Nesta sexta-feira, analisamos tensões no mercado farmacêutico global e avanços na edição genética, começando pelo alerta da EMA sobre o momento crítico no acesso a novos medicamentos na Europa, impactado por políticas de preços internacionais. Detalhamos a atualização do CDC sobre o aumento de viroses respiratórias não-COVID, como o VSR e o Estreptococo do grupo A, e o que isso muda no diagnóstico diferencial na atenção primária. Por fim, abordamos no Radar uma pesquisa experimental que utiliza a ferramenta CRISPR-XIST para silenciar o cromossomo extra na Síndrome de Down.Afya News. Informação médica confiável e atualizada no seu tempo.Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/24-04-2026
There are few neurodegenerative diseases as devastating as Huntington's. It's sometimes likened to having Parkinson's, ALS and Alzheimer's all at the same time, with symptoms that include progressive motor dysfunction, cognitive decline and behavioural change. It's also hereditary — if a person has the faulty gene that causes the disease, there's a 50 percent chance their children will have it, too. In the fall of 2025, however, scientists announced that, for the first time, they could reduce the progression of Huntington symptoms using a new gene therapy. While that clinical breakthrough came with several caveats, it also heralded a possible new paradigm for drug discovery. In this episode, we explore how this innovative therapy works and what it could mean for the treatment of other rare diseases. Featured in this episode: Rachel Harding is an assistant professor in the department of pharmacology and toxicology at the University of Toronto and a principal investigator at the Structural Genomics Consortium. Her work on Huntington's disease has been recognized with major early-career awards, highlighting both scientific excellence and the potential patient impact of her research program. Further reading: Research is unravelling the mystery of what causes Huntington's disease, a devastating brain disease In a first, a gene therapy seems to slow Huntington disease “Best news” for Huntington's disease community comes with unanswered questions The Huntington's disease research pipeline World's first patient treated with personalized CRISPR gene editing therapy at Children's Hospital of Philadelphia Solve for X is brought to you by MaRS, North America's largest urban innovation hub and a registered charity. MaRS supports startups and accelerates the adoption of high-impact solutions to some of the world's biggest challenges. For more information, visit marsdd.com.
In part two of this two part episode, Jack continues their look into the dubious practice of “de-extinction” this time as it is pushed in the 21st century by Colossal BioSciences. Created in 2019 by Ben Lamm and George Church, Colossal aims at making extinction, as well as the endangered species list, a thing of the past using CRISPR technology. Claiming to have revived the Dire Wolf and Red Wolf, the company actually has been more successful in massive PR campaigns and paying off critics than reversing species death. But who benefits when people believe that the ecosystem can be preserved through test tubes rather than policy aimed at protecting endangered animals? You guessed it: wealthy sociopaths who see traditional conservation efforts as a barrier to total planetary domination. Gimmie Truth by Brad Abrahams https://bradabrahams.net/independent/gimme-truth-be7s6 Subscribe for $5 a month to get all the premium episodes: www.patreon.com/qaa Check out our new podcast series network Cursed Media! Spectral Voyager Season 2 is releasing now! Binge the entirety of Truly Tradly Deeply by Annie Kelly and Megan Kelly as well as Science in Transition by Liv Agar and Spencer Barrows: cursedmedia.net Produced by Liv Agar & Corey Klotz. Theme by Nick Sena. Additional music by Pontus Berghe. Theme Vocals by THEY/LIVE (instagram.com/theyylivve / sptfy.com/QrDm). Cover Art by Pedro Correa: (pedrocorrea.com) qaapodcast.com QAA was known as the QAnon Anonymous podcast.
In this episode of Biotech Breakthroughs, Matt Phipps, group head of biotech research, speaks with William Blair biotech analyst Myles Minter about how gene editing is moving from early hype toward clinically validated therapies. They discuss lessons from the first approved ex vivo product and highlight key 2026 catalysts across CRISPR, base editing, RNA editing, and DNA writing.
Weichert details the downfall of Charles Lieber, a Harvard scientist and DARPA researcher recruited by the Thousand Talents Program to mirror his nanotechnology work in Wuhan, later convicted for making false statements and hiding Chinese bank accounts. The discussion shifts to CRISPR technology and He Jiankui's controversial genetic splicing on human twins, which reportedly resulted in unintended brain augmentations. Weichert warns that China views biotechnology as "dual-use," meaning advancements intended for civilian health are simultaneously being weaponized by the People's Liberation Army. (2)1937 SHANGHAI IMPERIAL JAPANESE NAVY FLAGSHIP
After talking about health as we always do because we're old, we pivot to diet — specifically veganism. Cori, who has never cared about animal rights, gamely steel-mans an argument in favor, while Nina, whose bleeding heart has caused anemia and possibly brittle bones, fearfully argues against. Along the way we cover tribes, rituals, purity, CRISPR, evolution, Lierre Keith, lactose tolerance, lactation intolerance, the Bible, abattoirs, eggs, nuts, Jordan Peterson, cults, The Liberation Pledge, and how Nina accidentally killed a bat when she was 17.Since recording this on Passover 2026 (release delay 85% Cori's fault) Nina worked through more of her apostasy, first writing The Law of Conservation of Evil and then Vegan Appreciation Day. She's done now.Links:The Vegetarian Myth by Lierre Keith: https://www.lierrekeith.com/book-ex_the-vegetarian-myth.phpSoylent (Creamy Chocolate is the only good flavor): https://www.amazon.com/Soylent-Chocolate-Protein-Replacement-Bottles/dp/B08H6FB43L?th=1Nina's Fecebook solicitation: https://www.facebook.com/nina.paley/posts/pfbid0EcMpKSUVyGm6356iEw8VeJXzRJhSP5X3YyVZkDKrUAVrMrYC4oUR3fMriQ8vA2xtlNina's poll on Spinster: https://spinster.xyz/@ninapaley/posts/B4tQFS5G2srXYSm1LcNina's poll on Twitter:Jordan Peterson's Lion Diet: https://liondiet.com/the-diet-updated-march-2018/The Liberation Pledge: https://veganfta.com/blog/2022/11/16/what-is-the-liberation-pledge-and-how-hard-is-it/Vegan TERFFles (out of stock) (password: vegan): https://store.ninapaley.com/product/vegan-terffles/Vegan Appreciation Day: https://ninapaley.com/2026/04/09/vegan-appreciation-day/The Law of Conservation of Evil: https://ninapaley.com/2026/04/04/the-law-of-conservation-of-evil/ Get full access to Heterodorx Podcast at heterodorx.substack.com/subscribe
Send us Fan MailIn this episode of Causes or Cures, Dr. Eeks sits down with transplant surgeon and author Dr. Josh Mezrich to talk about xenotransplantation—the use of animal organs, primarily from pigs, to try to address the massive shortage of human donor organs.More than 100,000 people in the U.S. are currently waiting for a transplant. For many, time runs out. Xenotransplantation offers a possible path forward, but it's not a simple one.This conversation walks through both sides.We talk about the history—from early, controversial experiments using primates to today's gene-edited pig organs—and what's actually happening right now in human patients. But we also spend time on the part that often gets pushed aside: the ethical questions.What are we asking of these animals?How are they treated in the process?And how do we weigh that against the possibility of saving human lives?We discuss:• The evolution of xenotransplantation and key scientific breakthroughs• Real-world cases of patients receiving pig organs• The role of CRISPR and genetically engineered pigs• Ethical concerns around animal welfare and the use of nonhuman primates in research• Whether focusing on animal organs shifts attention away from improving human organ donation systems• The risks, including cross-species disease transmissionDr. Mezrich also shares insights from his new book Every Living Creature, which explores both the promise and the discomfort of this field.Dr. Mezrich is a transplant surgeon and Professor at the University of Wisconsin, where he holds the Mark A. Fischer Chair in Transplantation and serves as Surgical Director of the kidney transplant program. His clinical and research work focuses on liver and kidney transplantation, including how factors like the microbiome and biomarkers influence organ quality. He is also the author of How Death Becomes Life and his latest book, Every Living Creature, which explores the science and ethics of xenotransplantation. Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show
In 2023, the FDA approved the first gene therapies to help treat people with sickle cell disease. The treatment is for patients 12 years and older, but what if you could use this technology before someone is born? That’s what some researchers, and others, believe is the hope for the future. The idea is to use CRISPR, a technology used to edit the genes of living beings, during in vitro fertilization. It is much easier said than done, but could be possible in theory. Ashley Smart is the associate director of the Knight Science Journalism Program at MIT. He is also a senior editor at Undark and reported on embryonic gene editing for the publication. He joins us to share how these treatments and technologies might work, as well as the current challenges and limitations.
El programa aborda la tragedia ferroviaria de Adamuz. Las víctimas exigen explicaciones y garantías, mientras el ministro Óscar Puente minimiza el problema, contradiciendo informes de la Guardia Civil que apuntan a la rotura de un carril. Se destaca la ayuda vecinal y la retirada policial. Los jueces de Madrid defienden al juez Peinado ante los ataques del Gobierno por investigar a Begoña Gómez, esposa de Pedro Sánchez. También se cita por tercera vez a "La Paqui" en el caso Koldo. La economía española concentra la riqueza en mayores de 65 años por la propiedad de vivienda, mientras los jóvenes enfrentan dificultades. La inflación reduce el poder adquisitivo. Expertos alertan sobre la insostenibilidad del sistema de pensiones, que duplica el crecimiento económico proyectado, y proponen reformas urgentes. Científicos estadounidenses avanzan en una investigación sobre el síndrome de Down, usando la edición genética CRISPR para silenciar el cromosoma 21 extra. El doctor Luis Montoliu del ...
Episode 8 of TSC Talks 3.0 Research... continuing on with the extensive history of the rare disease Tuberous Sclerosis Complex, the set up for data harvesting and gene editing and the inevitability of enhanced grid adhesion. Woohoo! Next episode I'm gonna go into mitigation and the upswing of the sitch. Links:mindandbodyexercises.comhttps://medium.comhttps://maescenter.comrockarch.orgtikvahhealthandwellness.comnih.govnih.govnutritiondiagnostics.com.aunih.govpsychologytoday.comnih.govmcgill.cachop.eduhttps://historyofvaccines.orgnih.govjpeds.comhttps://time.comnih.govnih.govnih.gov2minutemedicine.comnih.govnih.govsciencedirect.comnih.govcdc.govnih.govhttps://richd.orgnih.govwikipedia.orgempr.comhttps://historyofvaccines.orghttps://drgreenmom.commayoclinic.orgkaiserpermanente.orgnih.govkff.orgforbes.comitu.intciocoverage.comhttps://studyfinds.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
MAGIC MYTHOS AND MAGA - 04.13.2026 - #931 BestPodcastintheMetaverse.com Canary Cry News Talk #931 - 04.13.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By: Executive Producers Sir LX Protocol Baron of the Berrean Protocol*** Producers of TREASURE (CanaryCry.Support) Rebecca T, Cage Rattler Coffee Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM SIR IKE MEGA BOX GIVEAWAY - Rating/Review, screenshot, send to Sir Ike CanaryCrySupplyDrop@gmail.com TRUMP/BIBLICAL 9:49 Trump Deletes Post With Image Depicting Himself as Jesus After Backlash (Variety) → Gonz post comparing Trump to Pope with crying McConaughey Clip: Trump at WH addresses the image after food delivery * WW3 37:37 Trump Truth on Friday "Great Reset" (Truth) CENTCOM blockade on all Iranian ports CLIP: Full Blockade on Iranian Ports announced CLIP: Tankers on there way itro gulf of America "The Purpose of a System is what it Does" (Wiki) ELON/BEAST SYSTEM 1:19:56 Elon and magic thread Triumphal Arch EXECUTIVE PRODUCERS 2:02:15 SIR IKE SUPPLY DROP GIVEAWAY! - sir ike speakpipe speakpipe - nomemprunte, In honor of your new baby emu, I am running a new special this month. People can take an extra 5% off all Emu Wrangler Roasts with code: BABYEMU Toph Challenge UFO 2:12:20 Missing nuclear official becomes TENTH person tied to dark pattern surrounding US secrets (DailyMail) BEAST SYSTEM 2:29:15 Apple Says Southern Lebanon Villages Weren't Removed From Maps (Wired) CRISPR/DNA/FOOD 2:40:09 CRISPR CITRUS → Gonz post about CRISPR edited orange trees, 300K in Florida CALLED IT 2:47:54 Ready to rumble? Hunter Biden challenges Trump's sons to cage match (Reuters) PRODUCERS 2:55:45 END 3:07:46
Mickey Desai interviews Sherry Heyl about her book Learn to Love the Roller Coaster: Stories of Change, Resilience, and the Future to Come. They discuss how nonprofits can navigate rapid technological and social change by adopting a "creator mindset" rather than a "poverty mindset" or "survivor mindset." Sherry emphasizes that change is constant and accelerating (driven by AI, quantum computing, and CRISPR) but organizations can manage it by staying grounded in their values, making incremental changes collaboratively, and treating emerging tools like AI as interns rather than replacements. The conversation covers practical frameworks for organizational change, the emotional dimensions of transitions, and how to use AI thoughtfully without abandoning human creativity and connection. We welcome support of the Nonprofit SnapCast via Patreon. We welcome your questions and feedback via The Nonprofit SnapCast website. Learn more about Nonprofit Snapshot's consulting services.
O episódio de hoje aborda avanços preventivos e tecnológicos cruciais para a prática médica, começando por um estudo que demonstra a superioridade da vacina recombinante contra a influenza em adultos com obesidade grave, oferecendo uma resposta imunitária significativamente mais robusta. Analisamos os resultados revolucionários da terapia génica reni-cel, que utiliza a nuclease CRISPR-Cas12a para elevar os níveis de hemoglobina fetal e eliminar crises vaso-oclusivas na anemia falciforme. Por fim, discutimos os dados da nova pesquisa da AMA sobre a adoção da Inteligência Artificial: embora o uso profissional tenha dobrado, cresce a preocupação dos médicos com a perda de competências clínicas fundamentais e com a privacidade dos dados.Afya News. Informação médica confiável e atualizada no seu tempo.Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/10-04-2026
The history of Tuberous Sclerosis Complex.they're juicing it.Some queries related to the complexity of epigenetic variables and the overlords decision to focus on genetics only for the sake of "simplicity"...Just my opinion?I welcome all listeners and critical thinkers.
Timestamps: 0:00 Here's tech news molded into a bunny shape 0:12 Chinese RAM cheap, but Samsung ups price 1:31 Artemis II completes lunar fly-by 2:59 LinkedIn 'Browsergate' 5:07 QUICK BITS INTRO 5:16 Nvidia Neural Texture compression 6:03 Italian courts invalidates Netflix price hikes 6:39 OpenAI acquires TBPN 7:36 SpaceX IPO banks must use Grok 8:17 CRISPR gene editing to treat sickle cell illness NEWS SOURCES: https://lmg.gg/h1slF Learn more about your ad choices. Visit megaphone.fm/adchoices
Every year, MIT Technology Review publishes its list of the 10 most important emerging technologies — and every year, Simon Erickson breaks it down through an investor's lens. In this episode, Simon and Heather review MIT's breakthrough technology lists from 2023, 2024, and 2025 to see what's already become reality, then preview the 2026 list live from the MIT Tech Review website. From weight loss drugs and AI-powered search to small language models, next-gen nuclear, and generative coding — which technologies are actually investable right now, and which are still 3–5 years out? Simon walks through the MIT framework alongside the Gartner Hype Cycle and Boston Consulting Group's value creation index to help investors separate the signal from the noise.Whether you're tracking AI companions, sodium-ion batteries, robotaxis, CRISPR gene editing, or hyperscale data centers, this episode gives you the big-picture context to start positioning early in the technologies shaping our future.
In Episode 6 of TSC Talks Research 3.0, I finish up the discussion of CRISPR and TSC and the trajectory, I get into cannabis and the way they've deglimmered exploration of consciousness for those with rare diseases on hefty meds and how this relates to the cultivated biosphere that limits the full potential of the divine human. So many the templates for data and experimentation to build the current Healthcare 4.0 system and Precision Medicine. While many will be helped, there will be a dependence on the grid system.YouTube Video: https://youtu.be/OqLKIZ7Q54s?si=8svWmKHp4ekiFOnRLinks: https://www.liebertpub.com/doi/10.1089/crispr.2024.0079 https://pubmed.ncbi.nlm.nih.gov/39654514/ https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7793581/ https://innovativegenomics.org/news/crispr-clinical-trials-2026/ https://frontlinegenomics.com/sickle-cell-disease-a-2024-update/ epidiolexhcp.com nih.gov sciencedaily.com https://www.researchgate.net/publication/348347376_Gene_therapy_for_tuberous_sclerosis_complex_type_2_in_a_mouse_model_by_delivery_of_AAV9_encoding_a_condensed_form_of_tuberin globalgenes.org neurologylive.com berkeley.edu ccf.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
Xenotransplantation—the use of organs from other species to treat human disease—has long existed at the intersection of science fiction and surgical innovation. While early efforts were marked by limited success and ethical controversy, recent advances in genetic engineering, immunosuppression, and organ preservation have brought the field closer than ever to clinical reality.In this episode of Behind the Knife, we are joined by Dr. Joshua Mezrich to explore the history, science, and future of xenotransplantation. Through a narrative lens, we trace the evolution of transplantation from its earliest experimental days to the modern era of gene-edited porcine organs, highlighting key breakthroughs, ethical challenges, and the pioneers who shaped the field. We also examine the current state of clinical trials and what xenotransplantation may mean for the future of organ availability and transplant practice.Hosts - Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan - Joshua Mezrich, MD, Professor, University of Wisconsin School of Medicine and Public HealthLearning Objectives By the end of this episode, listeners will be able to:- Describe the historical evolution of xenotransplantation, including the primate and early porcine eras - Explain the key immunologic and biologic barriers to xenotransplantation, including hyperacute rejection and the role of natural antibodies - Summarize major scientific advances that enabled modern xenotransplantation, including cloning and CRISPR-based gene editing - Discuss recent clinical experiences and ongoing trials of xenotransplantation in humans - Evaluate the ethical considerations and societal implications of xenotransplantation - Consider the potential role of xenotransplantation in addressing organ shortage and reshaping transplant eligibility and allocationCheck out Dr. Mezrich's new book! https://www.amazon.com/Every-Living-Creature-Xenotransplantation-Change-ebook/dp/B0FH14LF6K***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6***Surgical Instrument FlashCards: https://app.behindtheknife.org/premium/surgical-instrument-flashcards Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US
Is a cathedral restoration a luxury or a mission? Lindsay Sant, Caroline Knight, and Lino Saubolle make the case for Melbourne's $190M "Light into the City" campaign — then turn to CRISPR-engineered mushroom protein and why scientists should never name products. The post Light into the City: Restoring St. Patrick’s Cathedral appeared first on StarQuest Media.
Seeds, seeds, seeds. It all starts with power and who controls the seeds. But who is actually building scalable companies in this space? Today we have one: a decentralised seed company in Uganda that only works with indigenous seeds, is farmer-owned, and gives power, value, and control back to the farmers. The farmers are trained to select seeds and to grow them, and Emmanuel Luwemba, the founder of Eden Seeds, helps sell the best varieties to other farmers without extracting all life from the countryside like most seed companies do.What about yields? Emmanuel went deep into what farmers actually need. Of course, yield is important, but so is profitability. Dirty little secret: hybrid seeds are often very expensive and need a lot of very expensive inputs to perform. They often don't perform in challenging circumstances (droughts, extreme weather, etc). Taste, flavour, and nutrition are important too. Indigenous seeds are naturally high in iron, for example and there's no need for a multimillion-dollar, donor-funded GMO or CRISPR project to change hybrid seeds to add extra iron. Just breed, grow, and eat the indigenous variety selected over time for iron. That's not to say we can't develop these seeds further or that they are frozen in time, of course we can and should. If indigenous seeds got a quarter of the funding hybrids get, they would outperform everyone.More about this episode.==========================In Investing in Regenerative Agriculture and Food podcast show we talk to the pioneers in the regenerative food and agriculture space to learn more on how to put our money to work to regenerate soil, people, local communities and ecosystems while making an appropriate and fair return. Hosted by Koen van Seijen.==========================
00:44 Why insects aren't massiveResearch Article : Snelling et al.11:39 Research HighlightsNature: Faster ticking of ‘biological clock' predicts shorter lifespanNature: Mighty mini-magnet is low in cost and light on energy use14:05 CRISPR creates CAR-T cancer therapy inside miceResearch Article: Nyberg et al.News & Views: A gene-editing method generates immunotherapeutic CAR T cells in the bodyNature: CRISPR makes enhanced cancer-fighting immune cells inside miceSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
In this episode I share information on the risks and side effects of CRISPR for individuals with TSC and in general as well as go into how those affected with TSC are "test bunnies" for much of this new technology, and my theories with documentation of why this is happening. I also go over some of the "no touch" technologies being rolled out and tested on those with diseases such as TSC where the nature of the genetics, a "monogenic" disorder, makes it a more suitable population to experiment on to gain information than other more common disorders, such as Alzheimer's, which involve 100s of genetic factors. TSC population is kept in that "test bunny" role without ever addressing the external factors that make the disease more difficult to manage in the first place.LINKS:pmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://cdmrp.health.mil/tscrp/defaulthttp://tuberous-sclerosis.org/research/tsa-funded-research/https://www.mdpi.com/2075-1729/15/3/368https://www.tscalliance.org/wp-content/uploads/2023/02/Training-Packet-Documents.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3010088/https://pmc.ncbi.nlm.nih.gov/articles/PMC4527140/https://pubmed.ncbi.nlm.nih.gov/19028034/https://pmc.ncbi.nlm.nih.gov/articles/PMC6851053/https://www.youtube.com/watch?v=hXRRq-dFuYghttps://www.youtube.com/watch?v=Hu2TvhhdEHYhttps://www.youtube.com/watch?v=BFuXttZspaYhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5727703/https://globalgenes.org/raredaily/transforming-tsc-epilepsy-with-a-precision-therapy/https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/https://pmc.ncbi.nlm.nih.gov/articles/PMC3164024/https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/https://www.biorxiv.org/content/10.1101/2024.02.22.581652v1.full-texthttps://pmc.ncbi.nlm.nih.gov/articles/PMC6408922/https://www.mdpi.com/2076-3417/14/3/1132https://pmc.ncbi.nlm.nih.gov/articles/PMC3744999/https://www.researchgate.net/publication/24217930_Magnetically_Responsive_Nanoparticles_for_Drug_Delivery_Applications_Using_Low_Magnetic_Field_Strengthshttps://pmc.ncbi.nlm.nih.gov/articles/PMC2933363/https://pmc.ncbi.nlm.nih.gov/articles/PMC7998448/https://pmc.ncbi.nlm.nih.gov/articles/PMC9230665/Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
Bill Maher sits down with neuroscientist Andrew Huberman to explore how smartphones, artificial light, and social media are reshaping how we think and connect. Huberman explains why morning sunlight and dark nights are critical for sleep, metabolism, and overall health. The two also dig into biohacking, peptides, and Big Pharma incentives, separating what's real from what's hype. They tackle shifting behavior, shrinking attention spans, and the future of health—from mRNA cancer treatments to CRISPR gene editing—along with more unsettling territory, including Jeffrey Epstein's connections to the scientific world. In the end, they land on a striking truth: “We don't relate to each other anymore—we relate through a screen." Support our Advertisers: High blood pressure can't wait. Get 20% off at https://www.120life.com and use code RANDOM Subscribe to the Club Random YouTube channel: https://www.youtube.com/c/clubrandompodcast?sub_confirmation=1 Watch episodes ad-free – subscribe to Bill Maher's Substack: https://billmaher.substack.com Subscribe to the podcast for free wherever you listen: https://bit.ly/ClubRandom Buy Club Random Merch: https://clubrandom.com Learn more about your ad choices. Visit https://podcastchoices.com/adchoices ABOUT CLUB RANDOM Bill Maher rewrites the rules of podcasting the way he did in television in this series of one on one, hour long conversations with a wide variety of unexpected guests in the undisclosed location called Club Random. There's a whole big world out there that isn't about politics and Bill and his guests—from Bill Burr and Jerry Seinfeld to Jordan Peterson, Quentin Tarantino and Neil DeGrasse Tyson—talk about all of it. For advertising opportunities please email: PodcastPartnerships@Studio71us.com ABOUT BILL MAHER Bill Maher was the host of “Politically Incorrect” (Comedy Central, ABC) from 1993-2002, and for the last fourteen years on HBO's “Real Time,” Maher's combination of unflinching honesty and big laughs have garnered him 40 Emmy nominations. Maher won his first Emmy in 2014 as executive producer for the HBO series, “VICE.” In October of 2008, this same combination was on display in Maher's uproarious and unprecedented swipe at organized religion, “Religulous.” Maher has written five bestsellers: “True Story,” “Does Anybody Have a Problem with That? Politically Incorrect's Greatest Hits,” “When You Ride Alone, You Ride with Bin Laden,” “New Rules: Polite Musings from a Timid Observer,” and most recently, “The New New Rules: A Funny Look at How Everybody But Me Has Their Head Up Their Ass.” FOLLOW CLUB RANDOM https://www.clubrandom.com https://www.facebook.com/Club-Random-101776489118185 https://twitter.com/clubrandom_ https://www.instagram.com/clubrandompodcast https://www.tiktok.com/@clubrandompodcast FOLLOW BILL MAHER https://www.billmaher.com https://twitter.com/billmaher https://www.instagram.com/billmaher Learn more about your ad choices. Visit podcastchoices.com/adchoices
Getting enough iron from the food we eat is something most of us take for granted, but about 2 billion people worldwide have an iron deficiency, the Number 1 nutritional deficiency globally. An international research team led by scientists in Brazil have come up with a way to boost iron content in rice, which is one of the most consumed foods. Farm Table Talk talks with Dr. Felipe Ricachenevsky about research at the Federal University of Rio Grande do Sul in Brazil, where he is working to biofortify rice with higher iron and zinc content through genetic modification using CRISPR technology. Felipe explained that approximately 25-30% of the world population lacks sufficient iron and zinc in their diets, particularly affecting children in developing countries where rice is a staple food. He explains his lab’s approach of combining two iron transporters to achieve a 50-70% increase in iron concentration in rice grains, though this came with some trade-offs in waterlogged conditions. The discussion also covered the broader context of genetic modification, including the challenges faced by Golden Rice and how public perception shifted from accepting genetic improvements to opposing them when they were primarily used for pesticide-resistant crops. felipecruzalta@gmail.com
If a species is horrible enough, do we have the right to kill it forever? Seventy years ago, a nightmare parasite feasted on the live flesh of warm-blooded creatures in North America: the screwworm. That is, until a young scientist named Edward F. Knipling discovered a crucial screwworm weakness and hatched a sweeping project to wipe them out. Knipling's seemingly zany plan to spray screwworms out of planes all over the continent— with US taxpayer money— succeeded, becoming one of humanity's biggest environmental interventions ever. Today, screwworms have been gone so long that none of us in North America even remember them. But now, they're coming back. And they're forcing us to ask: in an era of climate change and rapid mass extinction— should we kill off a species on purpose? Special thanks to James P. Collins, Max Scott, Amy Murillo, Daniel Griffin, Phil Kaufman, Katie Barnhill, Arthur Caplan, Ron Sandler, Yasha Rohwer, Aaron Keefe, Gwendolyn Bogard, Maria Sabate, Meredith Asbury, and Joanne Padrón CarneyEPISODE CREDITS: Reported by - Sarah Qari with help from - Latif Nasser Produced by - Sarah Qari Sound design contributed by - Sarah Qari Fact-checking by - Emily Krieger EPISODE CITATIONS: **The latest information on screwworm outbreaks and precautions: screwworm.gov Videos: Oral history interviews of Edward F. Knipling: here (https://zpr.io/njhMedFN5jsZ) and here (https://zpr.io/VQReQbfznCrq) Podcasts: Here's a Spotify playlist (https://zpr.io/PNMEM274G7vh) of all of our Golden Goose-inspired episodes! Sam Kean's podcast The Disappearing Spoon – his episode about screwworms is called The Screwiest and Perhaps Most Original Idea of the 20th Century (https://zpr.io/UYf6dR2yG3eN) Our episode on CRISPR & gene drives (https://zpr.io/UYf6dR2yG3eN) New to Radiolab? Check out our Radiolab Starter Kit (https://zpr.io/QpPnrHAZVQLR) playlist of all-time favorite episodes! Articles: Sarah Zhang's latest piece in The Atlantic: American Milk Has Changed (https://zpr.io/xebbdq2MWV4L) Her most recent piece on screwworms: The ‘Man-Eater' Screwworm Is Coming (https://zpr.io/ECmjCs7ScbS4) Her initial reporting on screwworms: America's Never-Ending Battle Against Flesh-Eating Worms (https://zpr.io/PNMEM274G7vh) Gregory Kaebnick's paper (https://zpr.io/yqNC3q5FbCcq) about screwworm eradication in Science Archival materials: The USDA's Screwworm Eradication Records (https://zpr.io/dY7zuVdGYKjf) contain lots of cool images and letters Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.
Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices
Patrick Bet-David and Rhonda Patrick explore AI's explosive rise, gene therapy, CRISPR, stem cell reprogramming, and longevity breakthroughs. They debate designer genetics, IQ enhancement, organ regeneration, and whether the future belongs to superhumans or authentic human imperfection.
Audra Lynn Fasano joins Tony to share her firsthand experience of being drawn into Jeffrey Epstein's network, beginning with her time at the Playboy Mansion and escalating into blackmail, intelligence ties, and operating as a middleman between elites. She recounts how threats against her family forced her deeper into the web, and why she believes Epstein was only one cog in a much larger machine. The conversation moves beyond trafficking into increasingly dark territory, ritual abuse, bloodline targeting, CRISPR technology, transhumanism, and what Audra sees as a modern Babylonian control system still unfolding today. She connects ancient sites, Nephilim lore, and elite funding networks to current technological initiatives, arguing that the end goal reaches far beyond exploitation. Through it all, Audra emphasizes spiritual warfare, deliverance, and returning to Christ as the only true protection in an escalating battle. This is a sobering discussion about power, deception, and why discernment may be more critical now than ever.Please pray for Tony's wife, Lindsay, as she battles breast cancer. Your prayers make a difference!If you're able, consider helping the Merkel family with medical expenses by donating to Lindsay's GoFundMe: https://gofund.me/b8f76890Become a member for ad-free listening, extra shows, and exclusive access to our social media app: theconfessionalspodcast.com/joinThe Confessionals Social Network App:Apple Store: https://apple.co/3UxhPrhGoogle Play: https://bit.ly/43mk8kZThe Counter Series Available NOW:The Counter (YouTube): WATCH HEREThe Counter (Full Episode): WATCH HEREThe Big Picture Prophecy Conference: prophecyconference26.comTony's Recommended Reads: slingshotlibrary.comIf you want to learn about Jesus and what it means to be saved: Click HereBigfoot: The Journey To Belief: Stream HereThe Meadow Project: Stream HereMerkel Media Apparel: merkmerch.comMy New YouTube ChannelMerkel IRL: @merkelIRLMy First Sermon: Unseen BattlesSPONSORSSIMPLISAFE TODAY: simplisafe.com/confessionalsGHOSTBED: GhostBed.com/tonyCONNECT WITH USWebsite: www.theconfessionalspodcast.comEmail: contact@theconfessionalspodcast.comAudra Lynn FasanoFacebook | Unseen Targets | Unseen Chains | Unseen SpiritsEpstein Justice - Click HereMAILING ADDRESS:Merkel Media257 N. Calderwood St., #301Alcoa, TN 37701SOCIAL MEDIASubscribe to our YouTube: https://bit.ly/2TlREaIReddit: https://www.reddit.com/r/theconfessionals/Discord: https://discord.gg/KDn4D2uw7hShow Instagram: theconfessionalspodcastTony's Instagram: tonymerkelofficialFacebook: www.facebook.com/TheConfessionalsPodcasTwitter: @TConfessionalsTony's Twitter: @tony_merkelProduced by: @jack_theproducerOUTRO MUSICJoel Thomas - "Rose In A Cage"YouTube | Apple Music | Spotify
HEADLINE: Charles Lieber and the CRISPR Threat. GUEST: Brandon Weichert. SUMMARY: Weichert highlights Charles Lieber's conviction and He Jiankui's unethical gene experiments, illustrating how China exploits dual-use biotechnology to advance military goals and defeat Western rivals.PEKING 1904
© 2020-2026 Ivy Podcast Discovery LLC
